Par Will Restate FY 2004, 2005 Results Due to Accounting Error
This article was originally published in The Pink Sheet Daily
Executive Summary
The restatement could lower actual revenues by $55 mil. over the period.
You may also be interested in...
Par's Megace ES Clears FDA; Company Will Target Generic Megestrol Users
Concentrated version of the appetite stimulant megestrol acetate oral suspension will launch the week of July 11 through Par's 59-rep sales force. The company expects to convert half the $60 mil. generic market for megestrol acetate oral suspension to Megace ES by the end of 2006.
Future BIO Global Efforts Include International Relations, Greenwood Says
HAMBURG, Germany - Due to the increasingly global nature of biotechnology, the Biotechnology Industry Organization's board of directors will meet next month to discuss a proposal to expand its global reach and potentially create a department of international relations, BIO President Jim Greenwood said Nov. 13
Hospira’s Mayne Event: Acquisition Strengthens Oncology Portfolio
Merger will create the leading generic injectable pharmaceutical company in the world.